Netherlands Lung Cancer Market Report with Executive Summary, Size, Analysis and Forecast to 2023-2028

Report Overview

The Europe lung cancer therapeutic market size stood at around USD 1.67 billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Netherlands has the third highest cancer rate in Europe. Amongst the different types of cancer, lung cancer was the top cause of death and disability combined in 2019 in Netherlands. It has been seen that incidence is greater above the age of 60; however, younger females are increasingly being impacted. Diagnosis usually occurs after metastasis, which decreases the chances of survival. The Dutch Government hopes to combat this rise with anti-smoking campaigns and is considering the implementation of lung cancer screening.

In 2017, expenditure on care for lung cancer amounted to a total of 456.7 million euros. This corresponds to 7.8% of the total expenditure on health care for new formation and 0.52% of the total expenditure on health care in the Netherlands. Of the health care expenditure for lung cancer, 398 million euros (87%) went to hospital care and medical specialist care.

Market Drivers

The market is majorly driven by the increasing burden of lung cancer in Netherlands. According to the Netherlands Cancer Registry (IKNL), the number of lung cancer cases were 23,966 in 2019 and 24,927 in 2020. The percentage increase in cases from 2019 to 2020, for females, was 1.3% as opposed to 0.4% in males. This is attributed to high numbers of female smokers. According to the Integrated Cancer Centre of Netherlands (IKNL), such high incidence of lung cancer is also caused due to lifestyle and genetic factors.

Another market driver is the increase in diagnosis and awareness.

Get Exclusive Free Sample Report @ https://www.prudentmarkets.com/sample-request/140083/

Top 5 Major Players

The top market players on the Netherlands Lung Cancer Market include Hoffman- La Roche Ltd., which is working on cancer immunotherapy to understand the immune system can be provoked into rejecting cancer in some patients, but not others.

Another top market player is AbbVie which has collaborated with Genmab to jointly develop and commercialise early-stage investigational bispecific antibody product

Other top players include AstraZeneca, Novartis

The report delivers the challenges in front of the Netherlands Lung Cancer Market 2023 that allows a better understanding of the market providing a helpful comprehensive evaluation and clear-cut dynamics associated with this market. The analyst has studied the current market scenario while concentrating on the new business objectives with the lucrative opportunities that are available. This report includes changes in customer requirements, customer preferences, and the vendor landscape in the industry with key factors that are expected to influence the overall dynamics of the Netherlands Lung Cancers Market including the current trends, growth opportunities, restraints, and market drivers.

To Know More About COVID-19 Impact On Netherlands Lung Cancer Market @ https://www.prudentmarkets.com/sample-request/140083/

Market Segmentation

By Type:

Non Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer and accounts for 80% of the cases. In this, tumor cells are of the same size or larger than the regular lung cells. It grows slowly, however, has a tendency for metastasis

Small Cell Lung Cancer (SCLC) accounts for 15% of lung cancer cases. In this, the tumor cells are smaller than regular lung cells and divide rapidly. The cancer has already metastasized by the time of diagnosis.

By Treatment Type:

By treatment type, the market is segmented into Surgery, Radiotherapy, and Systemic Therapy. Lung cancer surgery in Netherlands is very centralised due to strict quality restrictions which need to be followed. There are 19 radiation oncology centres in Netherland. Systemic therapy includes immunotherapy and chemotherapy

By Geography:

By geography, the market is segmented according to the 12 provinces in Netherlands- Groningen, Friesland, Drenthe, Overijssel, Flevoland, Gelderland, Utrecht, Noord-Holland, Zuid-Holland, Zeeland, Noord-Brabant and Limburg. The number of incident cases in 2020 were maximum in Zuid-Holland (2676), followed by Noord-Brabant (2317).

Top 5 Major Players--------------------------------------

The top market players on the Netherlands Lung Cancer Market include Hoffman- La Roche Ltd., which is working on cancer immunotherapy to understand the immune system can be provoked into rejecting cancer in some patients, but not others.

Another top market player is AbbVie which has collaborated with Genmab to jointly develop and commercialise early-stage investigational bispecific antibody product

Other top players include AstraZeneca, Novartis

The Netherlands Lung Cancer Market report is an easy-to-understand document giving section-wise details about the global market. Starting with the brief outline of the overall market, it will put forth the all-inclusive evaluated market statistics and different parameters for the forecast period. The report covers numerous aspects of the Netherlands Lung Cancer market divided into product kind, application, and end-use, offering the report to assist the customers in improving their ability to make precise decisions related to the business under the Netherlands Lung Cancer Market.

International Market Players will use the correct market facts and figures and applied math studies provided within the report back to perceive this and future growth of the worldwide Electrophoretic Netherlands Lung Cancer market. Each section of the research study is specially prepared to explore key aspects of the global Netherlands Lung Cancer Market. Buyers of the report will have access to accurate PESTLE, SWOT, and other types of analysis on the global Netherlands Lung Cancer market. Moreover, it offers highly accurate estimations on the CAGR, market share, and market size of key regions and countries.

This post-pandemic business planning research will aid clients to:
• Adjust their strategic planning to move ahead once business stability kicks in.
• Build resilience by making effective resource and investment choices for individual business units, products, and service lines.
• Conceptualize scenario-based planning to mitigate future crisis situations.

Instant Buy This Report and Get Up To 40% Discount [Use Corporate Email ID]: https://www.prudentmarkets.com/discount-request/140083/

Get full copy of 225+ pages research report (Inclusion of updated research on COVID-19) on United States Region at $1500 and, Europe region at $2000. Get in touch with our sales team, who will guarantee you a report that suits your needs.

Our qualified team of researchers, analysts, and consultants use in-depth qualitative research, quantitative research, and the latest recognized research techniques to offer an unrivaled level of detail and value to your research activities. Our market and competitive intelligence can be utilized by teams across multiple departments, including sales and business development, marketing, to:

• Access the latest information on potential competitors and customers through a comprehensive database
• Analyse the business strategies and collaborations of multiple companies within a specific market
• Identify new markets and regions for future expansion
• Compare financial trends between competitor companies
• Get to know about mergers and acquisitions
• Explore the strengths and weaknesses of companies cross-industry
• Improve your business modeling

Strategic Points Covered in Table of Content of Global Netherlands Lung Cancer Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Netherlands Lung Cancer market
Chapter 2: Exclusive Summary - the basic information of the Netherlands Lung Cancer Market.
Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges & Opportunities of the Netherlands Lung Cancer
Chapter 4: Presenting the Netherlands Lung Cancer Market Factor Analysis, Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.
Chapter 5: Displaying the by Type, End User and Region/Country
Chapter 6: Evaluating the leading manufacturers of the Netherlands Lung Cancer market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile
Chapter 7: To evaluate the market by segments, by countries and by Manufacturers/Company with revenue share and sales by key countries in these various regions
Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

(If you have any special requirements, please let us know and we will offer you the report as you want.)

Inquire Before Purchasing The Complete Report To Grow Your Business: https://www.prudentmarkets.com/enquiry-request/140083/

Contact Us:
Allan Carter
Andheri, Maharashtra, 400102
USA/Canada(Toll Free): 1800-601-6071
Direct Line: +91 83560 50278
Mail: sales@prudentmarkets.com
Web: www.prudentmarkets.com

About Us:
We are leaders in market analytics, business research, and consulting services for Fortune 500 companies, start-ups, financial & government institutions. Since we understand the criticality of data and insights, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. To be at our client's disposal whenever they need help on market research and consulting services. We also aim to be their business partners when it comes to making critical business decisions around new market entry, M&A, competitive Intelligence and strategy.

This release was published on openPR.